Together, these results suggest that RORγ antagonist alone or its combination with statin can be effective in inhibition of mCRPC tumor growth and that down-regulation of cholesterol biosynthesis program and up-regulation of cholesterol efflux genes are the underlying mechanisms. Here, RORC is linked to neoplasm.